Effects of Metformin on Glycaemic Control and Cardiovascular Risk in Type 2 Diabetes

2003 ◽  
pp. 47-52
Author(s):  
G. Perriello
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Glycaemic Control

P4-331: RELATIONSHIP BETWEEN GLYCAEMIC CONTROL AND COGNITIVE FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AT ELEVATED CARDIOVASCULAR RISK

2014 ◽  
Vol 10 ◽  
pp. P907-P908 ◽  
Author(s):  
Jolien Janssen ◽  
Esther van den Berg ◽  
Michaela Mattheus ◽  
Odd Erik Johansen ◽  
Geert Jan Biessels
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cognitive Function ◽  
Glycaemic Control

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

2003 ◽  
Vol 60 (3) ◽  
pp. 161-169 ◽  
Author(s):  
Giuseppe Derosa ◽  
Amedeo Mugellini ◽  
Leonardina Ciccarelli ◽  
Giuseppe Crescenzi ◽  
Roberto Fogari
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Glycaemic Control ◽  
Risk Profile ◽  
Cardiovascular Risk Profile

Glycaemic control and cardiovascular risk factors in Type 2 diabetes: a population-based study

1998 ◽  
Vol 15 (4) ◽  
pp. 304-307 ◽  
Author(s):  
G. Bruno ◽  
P. Cavallo-Perin ◽  
G. Bargero ◽  
M. Borra ◽  
N. D’Errico ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Glycaemic Control ◽  
Cardiovascular Risk Factors ◽  
Population Based ◽  
Population Based Study

scholarly journals Heart failure in diabetes: From an increased risk to a treatment target

2018 ◽  
Vol 21 (5) ◽  
pp. 399-403 ◽  
Author(s):  
Eberhard Standl
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Glycaemic Control ◽  
Treatment Target ◽  
Poor Glycaemic Control ◽  
Increased Risk

Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there has been an increasing concern regarding the cardiovascular (CV) safety profile of these agents. In view of this, FDA mandated the demonstration of cardiovascular risk-benefit profile of these agents through specifically designed CV outcome trials. Although we have several findings from these trials, none of them included HF as a primary endpoint indicating the need of trials focusing on HF. Here, we briefly discuss the results of the CV outcome trials in the context of HF.

Sign in / Sign up

Export Citation Format

Share Document